Clinical Trial: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Brief Summary: To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).

Detailed Summary: This is a prospective study of 15 consecutive eyes from 14 patients (One patients had NVG in both eyes at presentation.) with NVG presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between December 2008 and December 2009. Each eye received IVR (0.5 mg/0.05 ml) 1 week before TMC. Trabeculectomy was performed with fornix-based conjunctival flap method.
Sponsor: Siriraj Hospital

Current Primary Outcome: The change of intraocular pressure (IOP) [ Time Frame: Change of IOP between before trabeculectomy and at last visit ]

The change of intraocular pressure (IOP)between before trabeculectomy with mitomycin C (TMC) and after TMC. We compared this change at several time points such as at 6, 12 months and at last visit. The most important is the change of IOP between before TMC and at last visit as well as the level of IOP at last visit which is at of the longest follow-up time.


Original Primary Outcome: Same as current

Current Secondary Outcome: The safety of intravitreal ranibizumab (IVR) [ Time Frame: immediately after IVR ]

Blood pressure (mmHg) change


Original Secondary Outcome: Same as current

Information By: Siriraj Hospital

Dates:
Date Received: August 4, 2013
Date Started: February 2009
Date Completion:
Last Updated: August 13, 2013
Last Verified: August 2013